Mechanistically, OTUB1 attenuated tumor immunity in NSCLC and breast cancer by cleaving the K48-Ub of PD-L1 to prevent degradation of PD-L1 via the ERAD pathway (193, 194). Here, OTUB1 is linked to neoplasm.